Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/11351/8182
dc.contributor | Institut Català de la Salut |
---|---|
dc.contributor | [Lehnert T] Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. [Röver C] Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany. [Köpke S] Institute of Nursing Science, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. [Rio J] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Multiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Chard D] Department of Neuroinfammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK. National Institute for Health Research (NIHR), University College London Hospitals (UCLH) Biomedical Research Centre, London, UK. [Fittipaldo AV] Department of Oncology, Istituto Ricerche Farmacologiche “Mario Negri” IRCCS, Milano, Italy |
dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lehnert, Thomas |
dc.contributor.author | Röver, Christian |
dc.contributor.author | Köpke, Sascha |
dc.contributor.author | Rio Izquierdo, Jordi |
dc.contributor.author | Chard, Declan |
dc.contributor.author | Fittipaldo, Andrea Veronica |
dc.date | 2022-09-13T10:45:57Z |
dc.date | 2022-09-13T10:45:57Z |
dc.date | 2022-07-01 |
dc.identifier | Lehnert T, Röver C, Köpke S, Rio J, Chard D, Fittipaldo AV, et al. Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol. Syst Rev. 2022 Jul 1;11:134. |
dc.identifier | 2046-4053 |
dc.identifier | http://hdl.handle.net/11351/8182 |
dc.identifier | 10.1186/s13643-022-01997-2 |
dc.identifier | 35778721 |
dc.identifier | 000819782500002 |
dc.identifier.uri | http://hdl.handle.net/11351/8182 |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | BMC |
dc.relation | Systematic Reviews;11 |
dc.relation | https://doi.org/10.1186/s13643-022-01997-2 |
dc.rights | Attribution 4.0 International |
dc.rights | http://creativecommons.org/licenses/by/4.0/ |
dc.rights | info:eu-repo/semantics/openAccess |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Marcadors bioquímics |
dc.subject | Immunitat |
dc.subject | DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting |
dc.subject | Other subheadings::Other subheadings::/therapy |
dc.subject | CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors |
dc.subject | CHEMICALS AND DRUGS::Biological Factors::Biomarkers |
dc.subject | ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente |
dc.subject | Otros calificadores::Otros calificadores::/terapia |
dc.subject | COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios |
dc.subject | COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores |
dc.title | Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract | |
dc.description.abstract | |
dc.description.abstract | |
dc.description.abstract | |
dc.description.abstract |